

References

I-133

1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology, Breast cancer, V.2.2015 Invasive breast cancer. 2015.
2. Smith J, Vukelja S, Rabe A. et al. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients. *Breast Cancer Res Treat.* 2013;142:381–388.
3. Zeichner S, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. *Breast Cancer (Auckl).* 2016;10:25-36.
4. Liang X, Wu X, Hu C, et al. A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials. *Oncology Targets and Therapy.* 2016;9:4061-4074.
5. Andreopoulou, E and Sparano JA. Chemotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer: an overview. *Curr Breast Cancer Rep.* 2013;5(1):42-50. Accessed January 29, 2018.
6. Tolaney SM, Najita J, Sperinde J, et al. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. *Ann Oncol.* 2013;24(7):1841-1847. Accessed January 29, 2018.
7. Sachdev JC and Jahanzeb M. Use of cytotoxic chemotherapy in metastatic breast cancer: putting taxanes in perspective. *Clinical Breast Cancer.* 2016;16(2):73-81. Accessed January 29, 2018.
8. Micromedex®Solutions Compendia. 2019. Ixabepilone.
9. National Comprehensive Cancer Network (NCCN). Ixabepilone. NCCN Drugs and Biologics Compendium®. Breast Cancer, V.3.2017. Accessed January 24, 2018.
10. Ixabepilone. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018.
11. Ixempra® (Ixabepilone) for injection [package insert]. Princeton, NJ, R-Pharm US LLC. Revised 01/2016.